Acuta Capital Partners LLC Invests $1.29 Million in NewAmsterdam Pharma (NASDAQ:NAMS)

Acuta Capital Partners LLC purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 50,000 shares of the company’s stock, valued at approximately $1,285,000. NewAmsterdam Pharma accounts for approximately 1.3% of Acuta Capital Partners LLC’s holdings, making the stock its 25th largest position.

A number of other institutional investors have also recently made changes to their positions in NAMS. National Bank of Canada FI acquired a new stake in NewAmsterdam Pharma in the fourth quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter worth $80,000. Barclays PLC lifted its stake in shares of NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after buying an additional 7,199 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at $154,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter worth about $221,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

Analyst Ratings Changes

NAMS has been the topic of several research reports. Scotiabank increased their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 27th. Royal Bank of Canada reiterated an “outperform” rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Needham & Company LLC reaffirmed a “buy” rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a report on Monday, March 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $48.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $43.33.

NewAmsterdam Pharma Stock Up 4.7 %

Shares of NASDAQ NAMS opened at $20.03 on Friday. The firm has a 50-day simple moving average of $19.63 and a 200-day simple moving average of $21.21. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of -7.70 and a beta of -0.01. NewAmsterdam Pharma has a 52 week low of $14.06 and a 52 week high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. As a group, equities research analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Insider Buying and Selling

In related news, CAO Louise Frederika Kooij sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the transaction, the chief accounting officer now directly owns 15,000 shares in the company, valued at approximately $305,550. This represents a 90.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director James N. Topper acquired 1,135 shares of the business’s stock in a transaction that occurred on Wednesday, March 26th. The shares were acquired at an average cost of $22.49 per share, with a total value of $25,526.15. Following the completion of the transaction, the director now directly owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. The trade was a 0.04 % increase in their position. The disclosure for this purchase can be found here. 19.50% of the stock is currently owned by company insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.